Effect of a milk formula containing probiotics on the fecal microbiota of asian infants at risk of atopic diseases.
The fecal microbiota of 37 infants with (n = 20) or without (n = 17) probiotic administration was evaluated on D 3, and at 1, 3, and 12 mo by fluorescence in situ hybridization-flow cytometry (FISH-FC), PCR, and bacteriological culture methods. They represent consecutive subjects of an ongoing double-blind, placebo-controlled trial on a probiotic formula (LGG and Bifidobacterium longum) administered during the first 6 mo of life. Despite varying composition in each baby, there was a general bacterial colonization pattern in the first year. Bifidobacteria increased markedly (p = 0.0003) with a parallel decrease in Enterobacteriaceae (p < 0.001) and Bacteroides-Prevotella (p = 0.005) populations. Eubacterium rectale-Clostridium coccoides (p < 0.001) and Atopobium (p = 0.039) groups also gradually increased. This overall pattern was unaffected by probiotic administration (p > 0.05). B. longum (p = 0.005) and Lactobacillus rhamnosus (p < 0.001) were detected more frequently in probiotic group during supplementation, but no difference after supplementation had ceased (p > 0.05). Cultured lactic acid bacteria were also more numerous in the probiotic-administered babies during treatment period (log CFU/g 8.4 versus 7.4; p = 0.035). Our results indicate that supplemented strains could be detected but did not persist in the bowel once probiotic administration had ceased.
Mah
Ka Weng
KW
Department of Paediatrics, National University of Singapore, Singapore 119074.
Chin
Vanessa I L
VI
Wong
Wen Seen
WS
Lay
Christophe
C
Tannock
Gerald W
GW
Shek
Lynette P
LP
Aw
Marion M
MM
Chua
Kaw Yan
KY
Wong
Hwee Bee
HB
Panchalingham
Anushia
A
Lee
Bee Wah
BW
D044466:Asian People; D001431:Bacteriological Techniques; D001439:Bacteroides / Q000254:growth & development; D001644:Bifidobacterium / Q000235:genetics / Q000254:growth & development; D003013:Clostridium / Q000254:growth & development; D004269:DNA, Bacterial / Q000032:analysis; D004311:Double-Blind Method; D004755:Enterobacteriaceae / Q000254:growth & development; D005051:Eubacterium / Q000254:growth & development; D005243:Feces / Q000382:microbiology*; D005260:Female; D005434:Flow Cytometry; D041981:Gastrointestinal Tract / Q000382:microbiology*; D005865:Gestational Age; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000382:microbiology*; D017404:In Situ Hybridization, Fluorescence; D007223:Infant; D041943:Infant Formula / Q000008:administration & dosage*; D007231:Infant, Newborn; D052201:Lacticaseibacillus rhamnosus / Q000235:genetics / Q000254:growth & development; D008297:Male; D016133:Polymerase Chain Reaction; D018720:Prevotella / Q000254:growth & development; D019936:Probiotics / Q000008:administration & dosage*; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors
D004269:DNA, Bacterial